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This paper is a report of response rate (RR) and survival of 34 metastatic melanoma patients who received a dinitrophenyl (DNP)-
modified autologous melanoma cell vaccine. In all, 27 patients started the vaccine as a primary treatment for metastatic melanoma
and seven started it as an adjuvant, with no evidence of disease at the time, but had developed new metastases. Interleukin-2 (IL-2)
was administered in 24 out of the 34 patients: 19 who progressed on vaccine alone and five who had the combination from start.
Interleukin-2 was administered in the intravenous, bolus high-dose regimen (seven patients) or as subcutaneous (s.c.) low-dose
treatment (17). Overall response for the entire group was 35% (12 patients out of 34), 12% having a complete response (CR) and
23% a partial response (PR). However, only two patients had tumour responses while on the vaccine alone, whereas the other 10
demonstrated objective tumour regression following the combination with IL-2 (two CR, eight PR), lasting for a median duration of 6
months (range 3–50 months). Of the 12 responding patients, 11 attained strong skin reactivity to the s.c. injection of irradiated,
unmodified autologous melanoma cells. None of the patients with a negative reactivity experienced any tumour response. Patients
with positive skin reactions survived longer (median survival – 54 months). The results suggest enhanced RRs to the combination of
IL-2 and autologous melanoma vaccine. Skin reactivity to unmodified autologous melanoma cells may be a predictor of response and
improved survival, and therefore a criterion for further pursuing of immunotherapeutic strategies.
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Metastatic malignant melanoma is associated with grave prog-
nosis, not affected significantly by the varying treatment schedules.
Chemotherapy is usually the standard therapy, but it is associated
with considerable adverse reactions, and with the exception of a
minority of complete responders, most patients succumb to their
disease without any increase of survival. The combination of
chemotherapy with the biologic response modifiers interferon-a
(INFa) and interleukin-2 (IL-2) is associated with slightly higher
response rates (RRs), but this is achieved at the cost of more severe
toxicity (Atzpodien et al, 2002). Interleukin-2 can also be
administered alone. There is no agreed upon standard regimen
for IL-2, but the generally accepted protocols include intravenous
(i.v.), high-dose pulse therapy with 600–750000IUkg
 1dose
 1
(Atkins et al, 2000), continuous i.v. administration of
18 10
6IUm
 2day
 1 or less (Dillman et al, 1993), and the
decrescendo protocols, starting at 18 10
6IUm
 2dose
 1, and
decreasing. In the large series of Atkins et al (2000), the overall
response rate to high-dose IL-2 is 16%, with 6% achieving
complete tumour regressions. Lower doses of IL-2 alone, either
i.v. or subcutaneously (s.c.), are considered to yield responses only
rarely (Vlasveld et al, 1994).
Melanoma vaccines could have been an attractive alternative
approach, but that their effectiveness in metastatic disease is
limited: the RRs range from 5 to 15%, and the positive responses
are mainly limited to s.c. metastases (Mitchell et al, 1990; Morton
et al, 1992; Eton et al, 1998). Yet, a much higher proportion of
patients treated with melanoma vaccines develop definite immune
reactions. Although in most cases these reactions fall short of
being translated into clinical tumour regressions, improved
survival has been repeatedly reported for those patients who
develop antimelanoma immune responses (Bystryn et al, 1992;
Livingston et al, 1994; Hsueh et al, 2002; Baars et al, 2000). Only
few attempts of boosting the immune response to vaccines by the
addition of systemic doses of cytokines were made, mostly focused
on immunological rather than clinical parameters (Lee et al, 2001;
Maio et al, 2002). The natural candidate for boosting immune
responses induced by vaccines is IL-2. Most of the clinical Revised 13 October 2003; accepted 13 November 2003
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lexperience with IL-2 as an adjuvant to vaccine was gained with
high-dose schedules (Rosenberg et al, 1999) or when tumour cells
were transduced to secrete IL-2 (Osanto et al, 2000). The paucity of
clinical combination studies is surprising, in view of murine
models that strongly support their rationale (Schrayer et al, 2002;
Overwijk et al, 2003).
The present communication aims at reporting the outcomes
of such combination treatment. It is not a controlled clinical trial;
it is rather observations that nevertheless can shed some light
on the clinical value of combining autologous melanoma vaccine
with IL-2.
PATIENTS AND METHODS
Patients
The series includes 34 American Joint Committee on Cancer
(AJCC) stages III and IV melanoma patients with nonresectable
disease that were treated with an autologous melanoma cell
vaccine, conjugated with dinitrophenyl (DNP) and mixed with
BCG, at Hadassah University Hospital during the years 1996–2003
(Table 1).
All patients were evaluated prior to their inclusion with a total
body CT scan. In order to be eligible for the vaccine, patients had
to have undergone surgical removal of one tumour deposit and
have a Karnovsky performance status of X60%. Exclusion criteria
included brain metastases and the systemic use of corticosteroids.
Radiation and chemotherapy were not excluding criteria, as long
as 6 weeks had elapsed from the last treatment. Indeed, 22 of the
patients had undergone prior treatments, including isolated limb
perfusion (ILP), chemotherapy, irradiation or combination of
several of them. All these patients had documented tumour
progression following their last therapeutic regimen. Informed
consent was obtained from all patients.
Site of metastates included visceral sites (16 patients), dermal
and s.c. tissue alone (10 patients), lymph nodes (3), lymph nodes
and s.c. tissue (5). In all, 10 patients had more than one metastatic
site.
Treatment framework (Figure 1)
In total, 27 patients were diagnosed with nonresectable, active
metastatic melanoma on entry to the vaccination protocol. The
other seven patients were free of active disease at that time and
received the vaccine as an adjuvant treatment. They developed,
however, recurrence in the midst of the adjuvant protocol
(between vaccines 4 and 8; three patients) or within 2 years from
its initiation (four patients). These seven patients were described
elsewhere before (Lotem et al, 2002). They are included in the
present series because they continued vaccination in the presence
of active metastatic disease or were referred for successive IL-2
therapy.
Interleukin-2 was offered to all patients who had no tumour
regression after the initial four doses of the vaccine alone, as
concurrent treatment and to the patients who had recurrence
following the adjuvant autologous vaccine. Five patients with
metastatic disease received the combination right from start, as
initial vaccine and IL-2. Overall, 24 patients received a combina-
tion of vaccine plus IL-2.
Vaccine preparation
Tumour specimens were procured fresh and sterile. For large
tumour bulks, cells were extracted mechanically or by enzymatic
dissociation with collagenase and DNAse (Sigma, St Louis, MO,
USA), frozen in a controlled rate freezer and stored until needed in
liquid nitrogen in a medium containing 2.5% human albumin and
20% DMSO. If the total cell yield was less than 200 10
6 cells, cell
suspensions were put into culture bottles with Dulbecco’s modified
Eagle’s medium (DMEM, Gibco BRL, Gaithersburg, MD, USA),
10% fetal calf serum (Gibco BRL), HEPES (1:500), pen-strep
(1:100) and glutamin (1:100), and expanded to the required
number necessary for preparation of at least eight vaccine doses of
10–25 10
6 cells each. Culturing the cells resulted in the
preferential selection of melanoma cells, so that the vaccine finally
consisted of purified melanoma cells. Positive staining of more
than 50% of cells with at least one of the monoclonal antibodies S-
100 and HMB-45, using the alkaline phosphatase antialkaline
Table 1 Patients’ characteristics
Gender
Men 20
Women 14
Age (years)
Median 48.5
Range 11 75
Stage
III 13
IV 21
Site of metastases
Skin and s.c. alone 10
LNs7Skin and s.c. 8
Visceral 16
Lung 9
Liver 6
Bone 2
Ovary 1
Adrenal 1
Patients with more than one site
a 10
Treatment prior to vaccination
ILP 10
Chemotherapy 14
Irradiation 14
IFNa 3
s.c.¼subcutaneous; LN¼lymph node; ILP¼isolated limb perfusion;
IFNa¼interferon alpha.
aIncluding multiple visceral sites or visceral organ with s.c.
or LN metastases.
Therapeutic vaccination
(27 patients)
Adjuvant vaccination
(7 patients)
Initial
combination
with IL-2
Concurrent or
successive IL-2
Tumour response
no further
treatments
(three patients)
Other
treatments
(seven patients)
(Five patients)
(13 patients)
(Nine patients)
(Six patients)
(One patient)
Figure 1 Framework of treatment.
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lphosphatase (APAAP) reaction (Zymed Inc, San Fransisco, CA,
USA), was required.
On the day of treatment, the cells were thawed, washed and
irradiated to 110Gy. A sample was stained with trypan blue and
counted after irradiation. Conjugation of melanoma cells with DNP
was performed by the method of Miller and Claman (1976). Briefly,
melanoma cells were washed with Hank’s balanced solution–no
HSA (human serum albumin), resuspended to a concentration of
5 10
6ml
 1, mixed, incubated for 30min and washed again. Prior
to vaccination, an appropriate amount of BCG was added, starting
with a dilution of 1:50 and reaching 1:500–1000, according to the
resulting granuloma at vaccination site. Each vaccination dose was
composed of 10–25 10
6 melanoma cells.
Vaccination procedure
On Day 1, patients received 300mgm
 2 of i.v. cyclophosphamide.
On Days 4 and 5, patients were sensitised to DNP by applying
0.1ml of 2% DNP dissolved in acetone-corn oil (Sigma) topically
to the inner aspect of the arm. On Day 18, patients received a
second dose of 300mgm
 2 cyclophosphamide. On Day 21, the
prepared vaccine was injected into three adjacent sites on the
upper arm or thigh, avoiding limbs where lymph node dissection
had been performed previously. Seven additional doses of the
vaccine were administered at intervals of 21–28 days. Before
injecting the second dose of the vaccine, a third dose of
300mgm
 3 of cyclophosphamide was administered i.v.
Responding patients received additional doses of vaccine with
increasing intervals of 3, 3, 6 and 6 months.
IL-2 schedules
Interleukin-2 was administered in two different protocols: an
ambulatory low-dose protocol and an inpatient high-dose proto-
col.
IL-2 schedules were as follows:
(1) Low-dose, s.c. IL-2, given Days 1–5 every 14–21 days, reduced
to 3MIUday
 1 in patients over 70 years (two patients).
(2) High-dose IL-2, consisting of a 2-week course of therapy with
a 1-week rest interval in between. Patients were scheduled to
get up to 14 touching i.v. doses of IL-2 on each admission,
720000IUkg
 1 of IL-2 per dose, in a 15min rapid infusion.
Evaluation based on physical examination and imaging
analysis was performed 6–8 weeks after the first course.
Two patients received a second 2-week course. The actual
number of doses ranged between 7 and 14, with an average of
10.4 doses per course.
An overall of 24 patients received a combination of vaccine plus
IL-2. The first six patients were referred to the high-dose IL-2
protocol. The successive 18 received the low-dose protocol from
the start. Two of the low-dose patients who had a transient stable
disease and then progressed were referred to the high-dose
protocol. One of them died 10 days after treatment, with the
clinical presentation of Guillain Barre ´ syndrome. Four other
patients with lung metastases received daily inhalations with IL-2
9 10
6IUdose
 1 2day
 1, in addition to their s.c. injections of
low-dose IL-2.
Patients who received the combination therapy of vaccine with
initial or concurrent low-dose IL-2 were given IL-2 48h following
vaccination. The first two vaccination doses were always
administered without IL-2.
Patients were evaluated periodically every 2 months. These
evaluations included a physical examination, a complete blood
count and liver function tests. A total body CT scan was performed
every 2–3 months for the first 2 years, and thereafter at longer
intervals.
DTH evaluation
Skin testing to evaluate delayed-type hypersensitivity to auto-
logous melanoma cells was performed by the intradermal injection
of 1–3 10
6 unmodified melanoma cells irradiated to a dose of
170Gy. To avoid contamination with foreign proteins and
chemicals, the cells were triple washed before injection. DTH
was measured by the maximal diameter of erythema at 48h after
the injection of the vaccine. Erythema smaller than 5mm was
defined as a negative reaction. We arbitrarily chose the value of
10mm of erythema to discriminate between weak DTH (o10mm)
and strong DTH (X10mm). The skin test was performed on
vaccine doses 4 and 8. Patients were also skin tested to 3 10
6
unmodified autologous lymphocytes (Figure 2).
Definition of clinical response
Complete response (CR) was defined as a complete tumour
disappearance on imaging analysis or by direct palpation of skin
lesions, lasting for at least 3 months.
Partial response (PR) was defined as a reduction of 50% or more
of the sum of the greatest perpendicular dimensions of all
measurable lesions with no new lesions appearing elsewhere.
Stable disease was defined as a regression of less then 50% or
increase of no more than 25% in tumour size.
In two cases, we were unable to review the CT scans and had to
rely on a formal radiological report, comparing two successive
analyses, carried out 3 months apart, at another medical center
(cases 7 and 14, Table 3).
Statistical analysis
Survival time was calculated from the date of surgery to the date of
either last analysis or death. Duration of response was defined
from first vaccine or from first course of IL-2, depending on the
therapy that yielded the response.
The overall survival (OS) was estimated by the Kaplan–Meier’s
method. The impact of DTH response to autologous tumour cells
on OS was evaluated. Significance was calculated by the log-rank
test.
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Figure 2 Kaplan–Meier survival curve as a function of DTH response to
unmodified autologous tumour cells. Data available from 32 patients. DTH
test was not performed for two patients with a rapidly progressing disease.
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Survival analysis
In all, 34 patients are included in this series, with a median follow-
up of 21.5 months (range 4–74 months). Using the Kaplan–Meier
method and the log-rank test, the OS rate of the whole group is 40
months (standard error 5.0; 95% confidence interval 30.5–50.3
months). Patients who attained a strong positive DTH to their
autologous tumour cells had an OS from time of diagnosis of 54
months (standard error 13; 95% confidence interval 28–79
months) compared to 21 months (standard error 5; 95%
confidence interval 16–37 months) for those who had weak or
negative DTH, a difference found significant (P¼0.013, see
Figure 2). However, the difference may have been even larger,
since there are two patients with weak DTH who have exceptional
long-term survival that skewed the data of the whole group.
Response rates (Table 2)
Only two out of the 22 patients who went through a phase of
vaccine alone (other seven were adjuvant patients and five received
a combination from start) had demonstrated objective regressions
of their tumours (9%). Both had complete disappearance of s.c.
metastases after they had progressed following ILP. In addition,
one of these two had previously received chemotherapy with DTIC
and cisplatinum as well as local irradiation to the skin, without
success.
In contrast, 10 of 24 patients showed complete or partial
regression of their tumours, following the phase of IL-2 admin-
istration. The median duration of regression period was 6 months
(mean duration of 14 months), ranging from 3 to 50 months. Two
patients achieved CR, one of them is still in CR for 50 months, the
other recurred after 14 months. Of the eight patients with PR, two
still go on (4þ and 15þ months). Four of the responders had
their IL-2 combined with the vaccine from the beginning. Three of
the responders were participants of the adjuvant study that
recurred within 12–24 months and were then included in the low-
dose IL-2 regimen. The other three experienced disease progres-
sion during the course of vaccination, between vaccine doses 4 and
8, and were referred to high-dose IL-2. The patient with the long-
term CR is among them.
IL-2 schedules
Of the 17 patients who received low-dose IL-2, six had PR and
one had CR, a response rate of 41%. In comparison, three
of the patients who received high-dose IL-2 showed responses
(43%): one CR, two PRs lasting for 3 and 11 months. However,
the number of patients is too small to detect significant differences
of RRs. Notably, the tumour shrinkage induced by IL-2 was a
lengthy process that continued months after the last course of
high-dose IL-2, with no additional treatment. In patients receiving
low-dose IL-2, therapy was continued for as long as the response
was maintained. Patient 4 is treated with IL-2 for the longest
period, 15 months now and still demonstrates slow tumour
regression. Table 3 provides detailed clinical data on responding
patients.
Seven patients who progressed during their vaccination protocol
were not referred to receive IL-2: four because of rapidly
progressing disease, one who refused and two patients who
achieved CR following local irradiation of their tumour masses.
Figure 3 (A) Pelvic CT prior to initiation of low-dose IL-2, in a patient who received adjuvant autologous melanoma vaccine, and had recurrent pelvic LN
metastases 12 months later (patient 3). (B) Partial regression of pelvic lymph nodes after 6 months of therapy.
Table 2 Response rates
CR PR Stable Progressing
N%N%N% N %
Total (34 patients) 4 11.8 8 23.5 5 14.7 17 50.0
Vaccine only
a (22 patients) 2 9.1 0 — 1 4.5 19 86.4
Vaccine+IL-2 2 9.1 8 36.4 2 9.1 10 45.5
Low dose (17 patients) 1 5.9 6 35.3 2 11.8 8 47.0
High dose (seven patients) 1 20.0 2 40.0 0 — 2 40.0
aThe effect of vaccine treatment alone, before adding IL-2. CR¼complete response; PR¼partial response; IL-2¼Interleukin-2.
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Strong inflammatory reactions to autologous tumour cells
evaluated by the DTH test were evident in 20 patients (59%). Of
them, 11 (55%) attained a response to either vaccine alone (2) or
the combination (9). One responder had a DTH test of only 6mm.
In comparison, none of the 12 patients who failed to show a
positive DTH had any objective tumour regression. DTH data are
missing for two patients, who had a rapidly progressive disease.
Site of regressing metastases
In all, 12 patients had objective tumour regressions. These
regressions involved dermal and s.c. metastases in seven cases,
lung metastases in four, lymph node metastases in four and bone
in one.
Autoimmune phenomena
Two patients, both in whom tumour regressions occurred,
developed vitiligo. The vitiligo was most pronounced at the area
of regressing metastatic deposits (Figure 4). In one patient,
persistent elevated CPK levels were measured without electromyo-
graphic abnormalities. This patient had undergone ILP prior to his
immunisation.
DISCUSSION
The data presented here show an OS of 40 months after autologous
vaccine therapy of patients with metastatic melanoma. The
objective tumour regression to the vaccine, however, was minimal.
Only in two out of the 34 patients this regression was measurable.
These findings correspond with previous publications by the John
Wayne Cancer Institute (Hsueh et al, 2002), using an allogeneic
melanoma vaccine.
Yet, our retrospective series shows that upon the addition of IL-
2, RR rose to 42%. This considerable additional therapeutic benefit
suggests that the vaccine enhances the effect of IL-2 and increases
the RR to this cytokine. Any statements based on a small
retrospective series are limited, but the reported responses to IL-
2 therapy alone are in the order of 15–20% (Atkins et al, 2000),
and are particularly lower when low-dose IL-2 is administered
(Barth and Mule, 2000). It appears, therefore, that the autologous
vaccine exerted a priming effect, possibly generating tumour-
specific immune effector cells, which were activated upon the
addition of IL-2.
The administration of an autologous melanoma vaccine was
shown to be associated with the expansion of particular T-cell
clones within the tumour as well as in peripheral blood. This was
measured by post-therapy increment in antitumour cytolytic
activity, by increased cytokine production of lymphocytes to
tumour antigens and by rearranged TCR repertoire, which
indicates the expansion of specific clones, in peripheral blood or
within the tumour (Soiffer et al, 1998; Belli et al, 2002; Krause et al,
2002; Manne et al, 2002). DTH reaction to tumour cells is a useful
clinical test that reflects cell-mediated antitumour immunity. Both
CD4þ and CD8þ melanoma-reactive T-cell subsets were isolated
from skin biopsies of DTH sites (Waanders et al, 1997). Out of the
12 responding patients in the present series, 11 had developed a
strong positive DTH response to their autologous tumour cells.
None of the patients who failed to demonstrate a positive DTH
response had any objective tumour regressions, even with the
addition of IL-2. In a previous study, we found a significant
correlation between the development of strong positive DTH and
Table 3 Clinical data of patients achieving objective responses
Pt # Sex
Age
(year)
Previous treatments
for metastatic disease
Vaccine
setting
IL-2
protocol
Interval
between
vaccine
and IL-2
Site of
metastases
Type of
response
Site of
response
Duration
(months)
1 F 69 Surgery, ILP, DTIC
+cDDP, XRT
Metastatic No IL-2 Skin, leg and thigh CR Skin, leg
and thigh
42+
2 F 75 Surgery, ILP, XRT Metastatic No IL-2 Skin, leg CR Skin, leg 32+
3 F 71 Surgery, DTIC, XRT Adjuvant Low dose 12 mo Pelvic adenopathy PR Pelvic
adenopathy
(Figure 3)
10
4 M 58 Surgery, ILP, XRT Metastatic Low dose Concurrent Skin, leg; inguinal LN PR Skin,
inguinal LN
(Figure 4)
15+
5 F 55 Surgery, DTIC+cDDP
+low-dose IL-2
+GM-CSF, XRT
Metastatic Low dose Concurrent Brain resected;
paravertebral mass;
lung
PR Lung,
paravertebral
mass
3
6 F 44 Surgery, adjuvant
IHA fotemustine,
radiofrequency ablation
Adjuvant Low dose 24 mo Liver PR Liver 6
7 M 57 Surgery Metastatic Low dose
+inhalation
Concurent Lung, mediastinal LN PR
a Lung 3
8 M 68 Surgery Adjuvant Low dose
+inhalation
12 mo Lung PR Lung
(Figure 5)
4+
9 F 55 Surgery,
single dose of BCG
Metastatic Low dose
+inhalation
Concurrent Skin, thigh resected;
seven bilateral lung mets
CR Lung 14
10 M 52 Surgery, chemotherapy
(cDDP+DTIC, fotemustine),
pelvic perfusion with cDDP
Metastatic High dose 20 mo Skin, lower extremity;
pelvic LNs
PR Skin, lower
extremity;
pelvic LNs
11
11 F 28 Surgery, LD IFN,
ILP with melphalan
Metastatic High dose After eight
vaccinations
Skin, lower extremity;
pelvic LNs
CR Skin 50+
12 F 54 Surgery Metastatic Low dose and
later high dose
Concurrent Skin, lower extremity;
lung
PR
a Lung 3
cDDP¼cisplatinum; XRT¼radiotherapy; IHA¼intrahepatic artery infusion; HD¼high dose; LD¼low dose; IL-2¼Interleukin-2; ILP¼isolated limb perfusion; GM-
CSF¼granulocyte–macrophage colony-stimulating factor; IFN¼interferon; mo¼months; LN¼lymph node, CR¼complete response; PR¼partial response.
aBased on CT
report of another medical center; DTIC¼dacarbazine.
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Berd et al (1990, 2001) and Baars et al (2000). The results
presented here suggest that this is not only a prognostic marker
but may also be a prerequisite for tumour regression, attesting to
the presence of tumour-specific T cells. These preformed effectors
are probably the key to the enhanced effect of IL-2.
Interleukin-2 is a potent T-cell growth factor. This function of
IL-2 is the basis for the adoptive transfer of ex vivo-activated T
cells. High doses of IL-2 are required to sustain the growth and
proliferation of PBMC-derived tumour-reactive T cells and of
clonal tumour infiltrating lymphocytes that were expanded ex vivo,
after their reinfusion (Rosenberg et al, 1988; Dudley et al, 2002).
Immunisation with an immunodominant peptide derived from
gp100 antigen prior to the administration is a different, in vivo
approach to generate and expand peptide-specific T cells. This
regimen was associated with a 42% RR (Rosenberg et al, 1998). The
relatively high RR we have witnessed when IL-2 was given
following immunisation suggests that the whole tumour vaccine
may have generated tumour-reactive T-cell subsets. Interleukin-2
was probably required to turn these precursors into effector cells.
In spite of the fact that the series presented here is far too limited
to indicate advantage of low vs high doses of IL-2, it is nevertheless
encouraging to note that the less toxic protocol brought about
several prolonged responses.
A majority of the patients who responded by tumour regressions
have had s.c. or pulmonary deposits. The increased susceptibility
of skin and lung metastases to immunotherapy has been addressed
before (Berd et al, 2001; Hsueh et al, 1999). Interestingly, several of
our responding patients had received cytodestructive modality
previously: ILP or radiotherapy, to which they responded by
transient initial response. We assume that a treatment associated
with cell damage might have exposed the patients to release
tumour antigens. This constitutes the basis for combining
chemotherapeutic agents with IL-2, which clearly has no direct
antitumour cytotoxicity. The combination results in higher RRs
(Eton et al, 2002).
It is impossible to draw decisive conclusions based on a
small retrospective series. Yet, the RR to combined vaccine
and IL-2 treatment reported here is much higher than the
known effect to the cytokine therapy alone, which cannot be
overlooked. Patient selection for these protocols can be based on
the location of their metastatic deposits, preferring lung and
skin, as well as on positive DTH to autologous melanoma
cells. Clinicians who practice antitumour vaccination may wish
to try to proceed with an IL-2-based regimen in the appropriate
patients.
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Figure 4 (A) Regressing dermal metastases with perilesional vitiligo in patient 4. (B) Melanin-laden melanophages in upper dermis, in a skin biopsy from a
regressing lesion of patient 4 (H&E 20). (C) White hair arising from regressed s.c. metastases. Hair of noninvolved skin is fully melanised (patient 11).
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